Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon Medical completes trial of HIV therapeutic filtration device

Aethlon Medical : 26 January, 2009  (Company News)
Aethlon Medical has completed the 'first-in-man' study of a medical device designed to treat Human Immunodeficiency Virus (HIV).
In the study, an HIV-infected individual completed a twelve treatment study of the Aethlon Hemopurifier administered thrice weekly over the course of 30 days.

The Hemopurifier is a therapeutic filtration device that serves as an artificial adjunct to the immune system. In HIV care the Hemopurifier targets the clearance of all circulating strains of infectious HIV, including those varieties that cause patients to fail antiviral drug regimens. Additionally, the device assists to preserve immune response through the removal of gp120 and other toxic proteins shed by HIV to kill-off immune cells, the hallmark of AIDS. The study was conducted at the Sigma New Life Hospital in Punjab, India. Initial viral load and immune cell data resulting from the study are expected to be available for disclosure in mid-February.

'Based on previous treatment outcomes in Hepatitis-C patients, we are cautiously optimistic that the data resulting from our first HIV study will also prove to be positive,' stated Jim Joyce, chairman and chief executive officer of Aethlon Medical. 'The principal investigator of our study has reported all twelve Hemopurifier treatments were completed without any observed adverse events, and that the patient feels an improved sense of well being, including increased energy and appetite,' concluded Joyce.

In a previous infectious disease study, treatment with the Hemopurifier resulted in robust viral load reductions in Hepatitis-C (HCV) infected patients who completed a treatment protocol of three, 4-hour Hemopurifier treatments every other day during the course of one week. The study was conducted at the Fortis Hospital in Delhi, India.

Patient 1 had a 95 percent reduction three days post treatment and 89 percent reduction seven days post treatment. The initial viral load for patient 1 was 5.3 x 10(5) viral units per ml of blood (IU/ml). Patient 1's viral load seven days post treatment was 5.7 x 10(4) IU/ml.

Patient 2 had a 85 percent reduction three days post treatment and 50 percent reduction seven days post treatment. The initial viral load for patient 2 was 9.2 x 10(6) IU/ml. Patient 2's viral load seven days post treatment was 4.6 x 10(6) IU/ml.

Patient 3 had a 60 percent reduction three days post treatment and 83 v reduction seven days post treatment. The initial viral load for patient 3 was 3.0 x 10(8) IU/ml. Patient 3's viral load seven days post treatment was 5.1 x 10(7) IU/ml. All viral load measurements were performed with real-time quantitative polymerase chain reaction (RT-PCR). Control samples were measured in duplicate while treatment samples were generally measured in triplicate.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo